Brochures

Syngene offers GLP-certified viral testing and clearance services with flexible scheduling and rapid turnaround, supporting over 100 global clinical programs. Their facility is India’s only GLP-certified site for viral safety studies, ensuring compliance with FDA, EMA, and WHO regulations. Services include viral clearance studies, cell bank testing, and in-process/batch testing for biologics.

Every biologics journey begins with uncertainty. That’s why, at Syngene, we take the first step for you. We initiate Cell Line Development immediately, saving you up to four months while you secure approvals and funding. This early action places your program on a solid footing, reducing both technical and timeline risks. This isn’t just a service, but a clear signal that we’re already invested in your success at scale. Let’s accelerate your molecule to market – together.

Built on a proprietary CHO cell line and transposon-based technology, SynWeave™ enables the rapid generation of high-yield, stable, and homogeneous clones. The platform integrates advanced clone screening using the Ambr-250 bioreactor, allowing for comprehensive evaluation of titer, key product quality attributes, and process parameters, accelerating your path to robust cell line development.

Our expanded biologics manufacturing facility in Bayview, Maryland marks a strategic step forward in meeting the growing needs of our global customers. The addition of this facility increases Syngene’s total single-use bioreactor capacity to 50,000 liters, featuring 2,000 and 4,000 liters bioreactors designed to deliver economies of scale.

Syngene offers an integrated bioconjugation platform for XDCs, providing end-to-end support from antibody discovery to GMP manufacturing at up to 1 kg scale. Their expertise covers diverse conjugation technologies, payload and linker chemistry, and advanced analytical and bioassay support. Syngene ensures single-source manufacturing of antibodies, peptides, oligonucleotides, payloads, and linkers, minimizing risk and delays.

Syngene helps biopharma companies accelerate large molecule therapies to market through integrated biologics CDMO services, with manufacturing facilities across the U.S. and India. With a GMP capacity of 50 KL in single-use bioreactors, featuring 500 L, 2000 L and 4000 L units designed to deliver economies of scale, Syngene offers innovative, flexible, and efficient solutions to its clientele.